Sulfacetamide Sodium and Prednisolone Sodium Phosphate

Ingredient matches for Sulfacetamide Sodium and Prednisolone Sodium Phosphate

Prednisolone

Prednisolone 21-(disodium phosphate) (a derivative of Prednisolone) is reported as an ingredient of Sulfacetamide Sodium and Prednisolone Sodium Phosphate in the following countries:

• United States

Sulfacetamide Sodium

Sulfacetamide sodium salt (a derivative of Sulfacetamide) is reported as an ingredient of Sulfacetamide Sodium and Prednisolone Sodium Phosphate in the following countries:

• United States

International Drug Name Search

Ceftriaxone Tabuk

Ceftriaxone Tabuk may be available in the countries listed below.

Ingredient matches for Ceftriaxone Tabuk

Ceftriaxone

Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Ceftriaxone Tabuk in the following countries:

• Oman

International Drug Name Search

Pred fort

Pred fort may be available in the countries listed below.

Ingredient matches for Pred fort

Prednisolone

Prednisolone 21-acetate (a derivative of Prednisolone) is reported as an ingredient of Pred fort in the following countries:

• Brazil

International Drug Name Search

Easylax

Easylax may be available in the countries listed below.

Ingredient matches for Easylax

Phenolphthalein

Phenolphthalein is reported as an ingredient of Easylax in the following countries:

• Israel

International Drug Name Search

Mevasrolin

Mevasrolin may be available in the countries listed below.

Ingredient matches for Mevasrolin

Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Mevasrolin in the following countries:

• Japan

International Drug Name Search

MEPACT

MEPACT may be available in the countries listed below.

UK matches:

• Mepact 4 mg powder for suspension for infusion (SPC)

Ingredient matches for MEPACT

Mifamurtide

Mifamurtide is reported as an ingredient of MEPACT in the following countries:

• Germany


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Chlormycin

Chlormycin may be available in the countries listed below.

Ingredient matches for Chlormycin

Chloramphenicol

Chloramphenicol is reported as an ingredient of Chlormycin in the following countries:

• Taiwan

International Drug Name Search

Pantid

Pantid may be available in the countries listed below.

Ingredient matches for Pantid

Pantoprazole

Pantoprazole is reported as an ingredient of Pantid in the following countries:

• Bangladesh

International Drug Name Search

Lido-Hyal

Lido-Hyal may be available in the countries listed below.

Ingredient matches for Lido-Hyal

Hyaluronidase

Hyaluronidase is reported as an ingredient of Lido-Hyal in the following countries:

• Italy

Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Lido-Hyal in the following countries:

• Italy

International Drug Name Search

Chloricol

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Chloricol

Chloramphenicol

Chloramphenicol is reported as an ingredient of Chloricol in the following countries:

• United States

International Drug Name Search

Baro-Cat

Generic Name: barium sulfate (Oral route, Rectal route)

BAR-ee-um SUL-fate

Commonly used brand name(s)

In the U.S.

• Bar-Test


• E-Z-Disk


• Readi-Cat


• Volumen

In Canada

• Acb


• Baro-Cat


• Barosperse Enema


• Colobar-100


• Epi-C


• Epi-Stat


• Esobar


• Esopho-Cat Esophageal Cream


• E-Z-Cat


• E-Z-Hd


• E-Z-Jug


• E-Z-Paque

Available Dosage Forms:

• Kit


• Suspension


• Powder for Suspension


• Enema


• Paste


• Tablet


• Liquid

Therapeutic Class: Diagnostic Agent, Radiological Contrast Media

Uses For Baro-Cat

Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

Barium sulfate is taken by mouth or given rectally by enema. If taken by mouth, it makes the esophagus, the stomach, and/or the small intestine opaque to the x-rays so that they can be "photographed". If it is given by enema, the colon and/or the small intestine can be seen and photographed by x-rays.

The dose of barium sulfate will be different for different patients and depends on the type of test. The strength of the suspension and tablet is determined by how much barium they contain. Different tests will require a different strength and amount of suspension (some may require the tablet form), depending on the age of the patient, the contrast needed, and the x-ray equipment used.

Barium sulfate is to be used only by or under the direct supervision of a doctor.

Before Using Baro-Cat

In deciding to use a diagnostic test, any risks of the test must be weighed against the good it will do. This is a decision you and your doctor will make. Also, other things may affect test results. For this test, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Although there is no specific information comparing use of barium sulfate in children with use in other age groups, this agent is not expected to cause different side effects or problems in children than it does in adults.

Geriatric

This contrast agent has been used in older people and has not been shown to cause different side effects or problems in them than it does in younger adults.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this diagnostic test. Make sure you tell your doctor if you have any other medical problems, especially:

• Asthma, hay fever, or other allergies (history of)—If you have a history of these conditions, the risk of having a reaction, such as an allergic reaction to the additives in the barium sulfate preparation, is greater

• Cystic fibrosis—The risk of blockage in the small bowel is greater

• Dehydration—Barium sulfate may cause severe constipation

• Intestinal blockage or perforation—Barium sulfate may make this condition worse

Proper Use of barium sulfate

This section provides information on the proper use of a number of products that contain barium sulfate. It may not be specific to Baro-Cat. Please read with care.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

Precautions While Using Baro-Cat

Make sure to drink plenty of liquids after the test. Otherwise, barium sulfate may cause severe constipation.

Baro-Cat Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Rare

• Bloating


• constipation (severe, continuing)


• cramping (severe)


• nausea or vomiting


• stomach or lower abdominal pain


• tightness in chest or troubled breathing


• wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Constipation or diarrhea


• cramping

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Baro-Cat side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Baro-Cat resources

• Baro-Cat Side Effects (in more detail)
• Baro-Cat Use in Pregnancy & Breastfeeding
• Baro-Cat Support Group
• 0 Reviews for Baro-Cat - Add your own review/rating

• Baro-Cat Prescribing Information (FDA)


• Baro-Cat oral and rectal Concise Consumer Information (Cerner Multum)


• Barosperse Prescribing Information (FDA)


• Barotrast oral and rectal Concise Consumer Information (Cerner Multum)


• E-Z-Cat Dry Prescribing Information (FDA)


• Entrobar Prescribing Information (FDA)


• Intropaste Prescribing Information (FDA)


• Liquid E-Z Paque Prescribing Information (FDA)


• Polibar ACB Prescribing Information (FDA)

Compare Baro-Cat with other medications

• Computed Tomography

Celiprolol Wörwag

Celiprolol Wörwag may be available in the countries listed below.

Ingredient matches for Celiprolol Wörwag

Celiprolol

Celiprolol hydrochloride (a derivative of Celiprolol) is reported as an ingredient of Celiprolol Wörwag in the following countries:

• Netherlands

International Drug Name Search

Spasmo-Rhoival TC

Spasmo-Rhoival TC may be available in the countries listed below.

Ingredient matches for Spasmo-Rhoival TC

Trospium

Trospium Chloride is reported as an ingredient of Spasmo-Rhoival TC in the following countries:

• Germany

International Drug Name Search

Sentinel Spectrum

Sentinel Spectrum may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sentinel Spectrum

Lufenuron

Lufenuron is reported as an ingredient of Sentinel Spectrum in the following countries:

• Australia


• Switzerland

Milbemycin Oxime

Milbemycin Oxime is reported as an ingredient of Sentinel Spectrum in the following countries:

• Australia


• Switzerland

Praziquantel

Praziquantel is reported as an ingredient of Sentinel Spectrum in the following countries:

• Australia


• Switzerland

International Drug Name Search

Ursomax

Ursomax may be available in the countries listed below.

Ingredient matches for Ursomax

Ursodeoxycholic Acid

Ursodeoxycholic Acid is reported as an ingredient of Ursomax in the following countries:

• Argentina

International Drug Name Search

Cefu-Hexal

Cefu-Hexal may be available in the countries listed below.

Ingredient matches for Cefu-Hexal

Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefu-Hexal in the following countries:

• South Africa

International Drug Name Search

Fintaxim

Fintaxim may be available in the countries listed below.

Ingredient matches for Fintaxim

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Fintaxim in the following countries:

• Chile

International Drug Name Search

Dilator

Dilator may be available in the countries listed below.

Ingredient matches for Dilator

Bambuterol

Bambuterol hydrochloride (a derivative of Bambuterol) is reported as an ingredient of Dilator in the following countries:

• Bangladesh

Isoxsuprine

Isoxsuprine hydrochloride (a derivative of Isoxsuprine) is reported as an ingredient of Dilator in the following countries:

• Peru

International Drug Name Search

Elebloc

Elebloc may be available in the countries listed below.

Ingredient matches for Elebloc

Carteolol

Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Elebloc in the following countries:

• Argentina


• Bahrain


• Oman


• Spain


• Taiwan

International Drug Name Search

Continuex

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Continuex

Pyrantel

Pyrantel tartrate (a derivative of Pyrantel) is reported as an ingredient of Continuex in the following countries:

• United States

International Drug Name Search

Renaton

Renaton may be available in the countries listed below.

Ingredient matches for Renaton

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Renaton in the following countries:

• Myanmar


• Singapore

International Drug Name Search

Grisoral

Grisoral may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Grisoral

Griseofulvin

Griseofulvin is reported as an ingredient of Grisoral in the following countries:

• Netherlands

International Drug Name Search

Captophar

Captophar may be available in the countries listed below.

Ingredient matches for Captophar

Captopril

Captopril is reported as an ingredient of Captophar in the following countries:

• Bahrain


• Oman

International Drug Name Search

Hovizol

Hovizol may be available in the countries listed below.

Ingredient matches for Hovizol

Omeprazole

Omeprazole is reported as an ingredient of Hovizol in the following countries:

• Philippines

International Drug Name Search

Docmeloxi

Docmeloxi may be available in the countries listed below.

Ingredient matches for Docmeloxi

Meloxicam

Meloxicam is reported as an ingredient of Docmeloxi in the following countries:

• Belgium

International Drug Name Search

Enalapril Hydrochlorothiazide Lareq

Enalapril Hydrochlorothiazide Lareq may be available in the countries listed below.

Ingredient matches for Enalapril Hydrochlorothiazide Lareq

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Enalapril Hydrochlorothiazide Lareq in the following countries:

• Spain

International Drug Name Search

Crede Ecto Tracypor

Crede Ecto Tracypor may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Crede Ecto Tracypor

Amitraz

Amitraz is reported as an ingredient of Crede Ecto Tracypor in the following countries:

• South Africa

Cypermethrin

Cypermethrin is reported as an ingredient of Crede Ecto Tracypor in the following countries:

• South Africa

International Drug Name Search

Iodovine

Iodovine may be available in the countries listed below.

Ingredient matches for Iodovine

Povidone Iodine

Povidone-Iodine is reported as an ingredient of Iodovine in the following countries:

• Greece

International Drug Name Search

Zemaira

In the US, Zemaira (alpha 1-proteinase inhibitor systemic) is a member of the drug class miscellaneous respiratory agents and is used to treat Alpha-1 Proteinase Inhibitor Deficiency.

US matches:

• Zemaira

Ingredient matches for Zemaira

Alpha1-protease inhibitor

Alpha1-protease inhibitor is reported as an ingredient of Zemaira in the following countries:

• United States

International Drug Name Search

Collu-Hextril

Collu-Hextril may be available in the countries listed below.

Ingredient matches for Collu-Hextril

Hexetidine

Hexetidine is reported as an ingredient of Collu-Hextril in the following countries:

• Benin


• Burkina Faso


• Cameroon


• Central African Republic


• Chad


• Congo


• Cote D'ivoire


• France


• Gabon


• Guinea


• Madagascar


• Mali


• Mauritania


• Mauritius


• Niger


• Portugal


• Senegal


• Togo


• Zaire

International Drug Name Search

Retavase

Generic Name: Reteplase
Class: Thrombolytic Agents
Chemical Name: 173-l-Serine-174-l-lysine-175-l-glutamine-173-527-plasminogen activator (human tissue-type)
Molecular Formula: C₁₇₃₆H₂₆₅₃N₄₉₉O₅₂₂S₂₂
CAS Number: 133652-38-7

Introduction

Thrombolytic agent; biosynthetic (recombinant DNA origin) form of human tissue-type plasminogen activator (t-PA).¹

Uses for Retavase

Acute MI

Management of selected cases of acute evolving transmural MI in conjunction with heparin and/or platelet-aggregation inhibitors (i.e., aspirin).^{1 2 3 4 7 15 16} Lysis of coronary artery thrombi associated with acute evolving transmural MI^{1 15 16} and the resulting reperfusion can improve ventricular function and reduce the incidence of CHF, cardiogenic shock, and associated post-MI mortality.^{1 2 3 7 8 16}

Clinical benefit diminishes as the time period from symptom onset to initiation of therapy increases.^{2 3 5 6 15 16 19} If possible, administer thrombolytic therapy within 30 minutes of hospital admission or first contact with the health-care system.^{15 16 19}

The American College of Chest Physicians (ACCP), AHA, and ACC recommend use of any approved thrombolytic agent (e.g., alteplase, reteplase, tenecteplase, streptokinase [no longer commercially available in the US]) in patients having ischemic symptoms for ≤12 hours and ST-segment elevation or new or presumed new left bundle-branch block, unless contraindications exist.^{15 16 19} ACCP states that reteplase may be used in patients with acute MI who can be treated within 6 hours of symptom onset; however, alteplase or tenecteplase is recommended.¹⁶

ACCP suggests thrombolytic therapy in high-risk patients with ischemic symptoms characteristic of an acute MI or hemodynamic compromise present for 12–24 hours who have persistent ST-segment elevation or left bundle-branch block with concomitant ST-segment elevation changes if primary PCI is not readily available.¹⁶ ACC and AHA state that thrombolytic therapy is reasonable within 12–24 hours of symptom onset in patients with persistent ischemic symptoms accompanied by ST-segment elevation, provided no contraindications exist.^{15 19}

Thrombolytic therapy may be reasonable in patients with true posterior MI presenting within 12 hours after onset of symptoms.^{15 16 19}

PE

Thrombolytic therapy suggested by ACCP in patients with acute massive embolism† accompanied by unstable hemodynamics who are not at risk for hemorrhage.¹⁷ However, ACCP states that use of thrombolytic therapy for treatment of PE remains controversial because of the lack of studies supporting this use and the high risk of bleeding.²⁰ (See Effects on Hemostasis under Cautions.)

Generally reserve IV thrombolytic therapy for those with PE accompanied by unstable hemodynamics (e.g., shock) who do not have major contraindications because of bleeding risk²⁰ or those with stable hemodynamics with other poor prognostic factors (e.g., marked dyspnea, anxiety and low oxygen saturation; elevated troponin concentrations indicating right ventricular microinfarction; echocardiographic evidence of right ventricular dysfunction, right ventricular enlargement on a chest computed-tomography scan).²⁰

Perform a rapid risk assessment to determine if thrombolytic therapy is appropriate; irreversible cardiogenic shock may occur if therapy is delayed in patients with evidence of hemodynamic compromise.²⁰

Retavase Dosage and Administration

General

• 
  

  Institute therapy as soon as possible after acute MI.^{1 3 4 5 6 15 16} (See Acute MI under Uses.)

  
  

Administration

IV Administration

For drug compatibility information, see Drug Compatibility under Stability.

Administer IV.¹

Do not add other IV substances, additives, or other drugs to reteplase solution and do not infuse anything else simultaneously through the same IV line.¹

If administered via an IV administration set that is used for infusing heparin, flush line with 0.9% sodium chloride or 5% dextrose solution prior to and following drug administration.¹

Reconstitution

Reconstitute with 10 mL of sterile water for injection without preservatives to provide a solution containing 1 unit/mL.¹ Use dispensing pin and diluent provided by the manufacturer.^{1 12}

If foaming (usually slight) occurs, leave the vial undisturbed for several minutes.¹ Gently swirl until the contents are completely dissolved; avoid shaking.¹

Rate of Administration

Administer over 2 minutes.¹

Dosage

Expressed in reteplase-specific units, but also may be expressed in mg; each reteplase-specific unit is equivalent to 1.74 mg.¹

Adults

Acute MI

IV

Total dose is 20 units, given as two 10-unit IV injections 30 minutes apart.¹

Lower doses of reteplase (two 5-unit doses 30 minutes apart) have been used in conjunction with a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor, heparin, and aspirin.^{13 14 15 16} (See Interactions.)

PE†

IV

ACCP suggests a total dose of 20 units, given as two 10-unit IV injections 30 minutes apart.¹⁷

Cautions for Retavase

Contraindications

• 
  

  Active internal bleeding.^{1 3 9 15 19}

  
  


• 
  

  History of cerebrovascular accident.^{1 8 15 16}

  
  


• 
  

  Recent intracranial or intraspinal surgery or trauma.^{1 9 15 16}

  
  


• 
  

  Intracranial neoplasm.^{1 7 15 19}

  
  


• 
  

  Intracranial vascular disease (i.e., arteriovenous malformation, aneurysm).^{1 7 15 19}

  
  


• 
  

  Known bleeding diathesis.^{1 7 15 19}

  
  


• 
  

  Severe uncontrolled hypertension.^{1 6 7 9 11 15}

  
  


• 
  

  History of intracranial hemorrhage.^{15 16 19}

  
  


• 
  

  Suspected aortic dissection.^{15 19}

  
  


• 
  

  Recent (within 3 months) facial trauma.^{15 19}

  
  

Warnings/Precautions

Warnings

Effects on Hemostasis

Possible bleeding, including internal bleeding at intracranial or retroperitoneal sites or bleeding from the GI, GU, or respiratory tract.¹ Superficial or surface bleeding at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or sites of recent surgical intervention also may occur.¹

Weigh increased risks of therapy against anticipated benefits in patients with recent major surgery (e.g., CABG), obstetric delivery, organ biopsy, previous puncture of noncompressible vessels, cerebrovascular disease, hypertension (SBP ≥180 mm Hg and/or DBP ≥110 mm Hg), hemostatic defects (e.g., secondary to severe hepatic or renal disease), recent GI (e.g., active peptic ulcer) or GU bleeding, or recent trauma.^{1 15} Also, weigh risks against benefits of therapy in patients with diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions.¹ Weigh risks against benefits in patients receiving concurrent oral anticoagulant therapy (e.g., warfarin).^{1 15} Weigh risks against benefits in patients with any condition in which bleeding constitutes a substantial hazard or would be particularly difficult to manage because of its location.¹

Initiate therapy only after careful screening for contraindications.¹

Minimize risk of bleeding by carefully selecting patients and monitoring all potential bleeding sites (e.g., sites of all venous cutdowns, arterial and venous punctures, needle punctures).¹ Avoid IM injections and nonessential handling of patient.¹ Perform invasive venous procedures carefully and as infrequently as possible.¹ Minimize arterial punctures.¹ Avoid arterial and venous invasive procedures in areas that are inaccessible to manual compression (e.g., internal jugular or subclavian punctures).¹ Use of an artery in an upper extremity is preferred if an arterial puncture is essential.¹ Apply pressure to the puncture site for ≥30 minutes followed by a pressure dressing and frequent inspection of the puncture site for bleeding.¹

If serious bleeding occurs, immediately discontinue anticoagulant therapy; heparin anticoagulation can be reversed with protamine sulfate.¹ Do not administer a second injection of reteplase if serious bleeding occurs with the first injection.¹

Cardiovascular Effects

Possible fatal cardiogenic shock, heart failure, cardiac arrest, recurrent myocardial ischemia or infarction, myocardial rupture, AV block, electromechanical dissociation, pericardial effusion, pericarditis, mitral regurgitation, cardiac tamponade, hypotension, pulmonary edema, or thromboembolism.¹

Weigh risks against anticipated benefits of therapy in patients with a high likelihood of left heart thrombus (e.g., mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, septic thrombophlebitis, or an occluded arteriovenous cannula at a seriously infected site.¹

Cholesterol Embolization

Possibly fatal cholesterol crystal embolization associated with invasive vascular procedures (e.g., cardiac catheterization, angiography, vascular surgery) and/or thrombolytic agents.¹ Clinical features of cholesterol embolism include livedo reticularis, “purple toe” syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, MI, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, and rhabdomyolysis.¹

Arrhythmias

Possible reperfusion-related arrhythmias (e.g., sinus bradycardia, accelerated idioventricular rhythm, VPCs, VT).^{1 6 10 11}

Have appropriate antiarrhythmic therapy available during and after administration.^{1 6}

Sensitivity Reactions

Sensitivity Reactions

Allergic-type (e.g., pruritus, rash, urticaria) or anaphylactoid reactions (e.g., dyspnea, hypotension) reported rarely.^{1 7 13}

Institute appropriate therapy if an anaphylactoid reaction occurs.¹

Readministration

Repeat courses not systematically studied.¹ Do not administer second dose if anaphylaxis occurs with first dose.¹

Specific Populations

Pregnancy

Category C.¹

Increases risk of therapy in pregnant women; weigh risks against benefits of therapy in pregnant women.¹

Lactation

Not known whether reteplase is distributed into milk.¹ Caution if used in nursing women.¹

Pediatric Use

Safety and efficacy not established in children <18 years of age.^{1 13}

Geriatric Use

Intracranial hemorrhage more common.^{1 4 5 6} Weigh risks of drug against potential benefits.¹

Hepatic Impairment

Weigh the risks of therapy against the potential benefits in patients with severe hepatic impairment.¹

Renal Impairment

Weigh the risks of therapy against the potential benefits in patients with severe renal impairment.¹

Common Adverse Effects

Bleeding.¹

Interactions for Retavase

Specific Drugs

Drug	Interaction	Comments
Abciximab	Increased risk of hemorrhage1 14 15 16	Concomitant use not recommended by some clinicians16 Use suggested by other clinicians in selected patients with no risk factors for bleeding15
Aspirin	Increased risk of hemorrhage1 14 15 16	Monitor carefully for bleeding, especially at arterial puncture sites1
Dipyridamole	Increased risk of hemorrhage1 14 15 16
Heparin	Increased risk of hemorrhage1 14 15 16	Monitor carefully for bleeding, especially at arterial puncture sites1
Warfarin	Increased risk of hemorrhage1 15 16	Weigh risks against anticipated benefits1

Retavase Pharmacokinetics

Distribution

Extent

Not known whether reteplase is distributed into human milk.¹

Elimination

Metabolism

Cleared by the liver and kidney.¹

Half-life

13–16 minutes.¹

Stability

Storage

Parenteral

Powder for Injection

2–25°C; protect from light.¹

Reconstituted solutions contain no preservative.¹ Preferably use solution immediately after preparation; may be used up to 4 hours after reconstitution if stored at 2–30°C.¹ Discard any unused solution after 4 hours.¹

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Drug Compatibility

Reteplase is incompatible with heparin.¹

Y-Site CompatibilityHID

Incompatible
Bivalirudin

ActionsActions

• 
  

  Binds to fibrin and converts plasminogen to plasmin.¹ Plasmin degrades the fibrin matrix of the thrombus.¹

  
  


• 
  

  Decreased fibrin affinity compared with alteplase.^{2 3 4 7 8 10}

  
  

Advice to Patients

• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses or recent surgery.¹

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^{1 6}

  
  


• 
  

  Importance of informing patients of other important precautionary information.¹ (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Reteplase

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	For IV use only	10.4 units (18.1 mg)	Retavase (with reconstitution kit containing sterile water for injection diluent and a double-ended sterile dispensing pin)	PDL BioPharma

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. PDL BioPharma, Inc. Retavase (reteplase, recombinant) injection prescribing information. Freemont, CA; 2006 Jan.

2. Topol EJ, Ohman M, Armstrong PW et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III trial. Circulation. 2000; 102:1761-5. [IDIS 454027] [PubMed 11023929]

3. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997; 337:118-23.

4. Cairns JA, Kenedy JW, Fuster V. Coronary thrombolysis. Chest. 1998; 114:(Suppl 5S):634-57S.

5. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999; 34:89-911.

6. Internation Liason Committee on Resuscitation. Guidelines 2000 for cardiopulmonary rsuscitation and emergency cardiovascular care: an international consensus on science. Part 7, section 1. Acute coronary syndromes (acute myocardial infarction). Circulation. 2000; 102(Suppl. I):I-172-203.

7. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995; 346:329-36. [IDIS 351255] [PubMed 7623530]

8. Smalling RW, Bode C, Kalbfleisch J et al et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995; 91:2725-32. [IDIS 348924] [PubMed 7758177]

9. Bode C, Smalling RW, Berg G et al et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996; 94:891-8. [IDIS 372165] [PubMed 8790022]

10. Tebbe U, von Essen R, Smolarz A et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol. 1993; 72:518-24. [IDIS 319465] [PubMed 8362764]

11. Neuhaus KL, von Essen R, Vogt A et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol. 1994; 24:55-60. [IDIS 332009] [PubMed 8006283]

12. Boehringer Mannheim Corporation, Gaithersburg, MD: Personal communication.

13. Centocor Inc., Malvern, PA: Personal communication.

14. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combinaiton reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet. 2001; 357: 1905-14.

15. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). 2004. From http://www.acc.org/clinical/guidelines/stemi/index.pdf and http://www.americanheart.org.

16. Goodman SG, Menon V, Cannon CP et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:708S-75S. [PubMed 18574277]

17. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2004; 126(Suppl):401S-28S. [IDIS 523841] [PubMed 15383479]

19. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I):IV1-211.

20. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133 (Suppl): 454S-545S. [PubMed 18574272]

HID. Trissel LA. Handbook on injectable drugs. 14th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2007:1462.

More Retavase resources

• Retavase Side Effects (in more detail)
• Retavase Use in Pregnancy & Breastfeeding
• Retavase Drug Interactions
• Retavase Support Group
• 0 Reviews for Retavase - Add your own review/rating

• Retavase Prescribing Information (FDA)


• Retavase Concise Consumer Information (Cerner Multum)


• Retavase Advanced Consumer (Micromedex) - Includes Dosage Information


• Retavase MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Retavase with other medications

• Heart Attack

Contral

Contral may be available in the countries listed below.

Ingredient matches for Contral

Loratadine

Loratadine is reported as an ingredient of Contral in the following countries:

• Bosnia & Herzegowina


• Croatia (Hrvatska)

Omeprazole

Omeprazole is reported as an ingredient of Contral in the following countries:

• Indonesia

International Drug Name Search

Oyster-D

Generic Name: calcium and vitamin D combination (KAL see um and VYE ta min D)

Brand Names: Calcarb with D, Calcet, Calcio Del Mar, Calcitrate with D, Calcium 600+D, Caltrate 600 with D, Caltrate 600 with D Plus Soy, Caltrate Colon Health, Citracal + D, Citracal 250 mg + D, Citracal Creamy Bites, Citracal Maximum + D, Citracal Petites, Citrus Calcium with Vitamin D, Dical-D, Os-Cal 250 with D, Os-Cal 500 + D, Os-Cal with D, Oysco 500 with D, Oysco D, Oyst-Cal-D, Oyster Shell Calcium with Vitamin D, Oyster-D, Oystercal-D, Posture-D H/P, Risacal-D

What is Oyster-D (calcium and vitamin D combination)?

Calcium is a mineral that is found naturally in foods. Calcium is necessary for many normal functions of your body, especially bone formation and maintenance.

Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body.

Calcium and vitamin D combination is used to prevent or to treat a calcium deficiency.

Calcium and vitamin D combination may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Oyster-D (calcium and vitamin D combination)?

Before you take calcium and vitamin D combination, tell your doctor if you have kidney disease, past or present kidney stones, heart disease, circulation problems, a parathyroid disorder, or if you are pregnant or breast-feeding.

Avoid taking any other vitamin or mineral supplements that contain calcium or vitamin D without first talking to your doctor.

Before taking calcium and vitamin D combination, tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

What should I tell my healthcare provider before taking Oyster-D (calcium and vitamin D combination)?

If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take calcium and vitamin D combination, tell your doctor if you have:

• kidney disease;


• past or present kidney stones;


• 
  

  heart disease;

  
  


• 
  

  circulation problems; or

  
  


• 
  

  a parathyroid gland disorder.

  
  

Talk to your doctor before taking calcium and vitamin D combination if you are pregnant. Talk to your doctor before taking calcium and vitamin D combination if you are breast-feeding.

How should I take Oyster-D (calcium and vitamin D combination)?

Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.

Take the calcium and vitamin D regular tablet with a full glass of water.

The chewable tablet should be chewed before you swallow it.

Store calcium and vitamin D combination at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include irregular heartbeat, stomach pain, nausea, vomiting, dry mouth, a metallic taste in your mouth, confusion, loss of appetite, constipation, weakness, headache, confusion, or fainting.

What should I avoid while taking Oyster-D (calcium and vitamin D combination)?

Avoid taking any other vitamin or mineral supplements that contain calcium or vitamin D without first talking to your doctor.

Oyster-D (calcium and vitamin D combination) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

• 
  

  an irregular heartbeat;

  
  


• 
  

  nausea, vomiting, or decreased appetite;

  
  


• 
  

  dry mouth;

  
  


• 
  

  constipation;

  
  


• 
  

  weakness;

  
  


• 
  

  headache;

  
  


• 
  

  a metallic taste;

  
  


• 
  

  muscle or bone pain; or

  
  


• 
  

  drowsiness.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Oyster-D (calcium and vitamin D combination)?

Before taking calcium and vitamin D combination, tell your doctor if you are taking:

• 
  

  digoxin (Lanoxin, Lanoxicaps);

  
  


• 
  

  antacids containing calcium, aluminum, or magnesium;

  
  


• 
  

  other calcium supplements;

  
  


• 
  

  calcitriol (Rocaltrol) or other vitamin D supplements; or

  
  


• 
  

  a tetracycline antibiotic such as demeclocycline (Declomycin), doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).

  
  

This list is not complete and there may be other drugs that can interact with calcium and vitamin D combination. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Oyster-D resources

• Oyster-D Use in Pregnancy & Breastfeeding
• Oyster-D Drug Interactions
• Oyster-D Support Group
• 0 Reviews for Oyster-D - Add your own review/rating

Compare Oyster-D with other medications

• Dietary Supplementation
• Osteoporosis

Where can I get more information?

• Your pharmacist can provide more information about calcium and vitamin D combination.

brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine

Generic Name: brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine (BROM fen IR a meen, KLOR fen IR a meen, METH skoe POL a meen, FEN il EFF rin, SOO doe ee FED drin)

Brand Names: SymPak II

What is brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine?

Brompheniramine, chlorpheniramine, and methscopolamine are antihistamines that reduce the effects of the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Phenylephrine and pseudoephedrine are decongestants that shrink blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

The combination of brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine is used to treat runny or stuffy nose, sneezing, itching, watery eyes, and sinus congestion caused by allergies, the common cold, or the flu.

Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine may also be used for purposes not listed in this medication guide.

What is the most important information I should know about this medication?

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. You should not use this medication if you have severe constipation, a blockage in your stomach or intestines, or if you are unable to urinate. Do not use cold medicine if you have untreated or uncontrolled diseases such as glaucoma, asthma or COPD, high blood pressure, heart disease, coronary artery disease, or overactive thyroid. Do not use a cold medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

What should I discuss with my healthcare provider before taking this medication?

Do not use a cold medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects. You should not use this medication if you have severe constipation, a blockage in your stomach or intestines, or if you are unable to urinate. Do not use cold medicine if you have untreated or uncontrolled diseases such as glaucoma, asthma or COPD, high blood pressure, heart disease, coronary artery disease, or overactive thyroid.

To make sure you can safely take this medication, tell your doctor if you have any of these other conditions:

• 
  

  a blockage in your digestive tract (stomach or intestines), a colostomy or ileostomy;

  
  


• 
  

  diabetes;

  
  


• 
  

  liver or kidney disease;

  
  


• 
  

  epilepsy or other seizure disorder;

  
  


• 
  

  cough with mucus, or cough caused by smoking, emphysema, or chronic bronchitis;

  
  


• 
  

  enlarged prostate or urination problems;

  
  


• 
  

  low blood pressure;

  
  


• 
  

  pheochromocytoma (an adrenal gland tumor); or

  
  


• 
  

  if you take potassium (Cytra, Epiklor, K-Lyte, K-Phos, Kaon, Klor-Con, Polycitra, Urocit-K).

  
  

FDA pregnancy category C. It is not known whether this medicine will harm an unborn baby. Do not use cough or cold medicine without telling your doctor if you are pregnant or plan to become pregnant while using the medicine. This medication can pass into breast milk and may harm a nursing baby. Antihistamines and decongestants may also slow breast milk production. Do not use a cough or cold medicine without telling your doctor if you are breast-feeding a baby.

How should I take brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine?

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Cold medicine is usually taken only for a short time until your symptoms clear up.

Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children.

Do not take for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache or skin rash.

If you need surgery or medical tests, tell the surgeon or doctor ahead of time if you have taken a cold medicine within the past few days. Store at room temperature away from moisture and heat.

What happens if I miss a dose?

Since cold medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include severe forms of some of the side effects listed in this medication guide.

What should I avoid while taking this medication?

This medicine may cause blurred vision and may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert and able to see clearly. Ask a doctor or pharmacist before using any other cold, allergy, cough, or sleep medicine. Antihistamines and decongestants are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine or decongestant. Drinking alcohol can increase certain side effects of this medication.

Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.

Avoid becoming overheated or dehydrated during exercise and in hot weather. This medication can decrease sweating and you may be more prone to heat stroke.

Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using this medicine and call your doctor at once if you have a serious side effect such as:

• 
  

  fast or uneven heart rate;

  
  


• 
  

  pounding heartbeats or fluttering in your chest;

  
  


• 
  

  mood changes;

  
  


• 
  

  tremor, seizure (convulsions);

  
  


• 
  

  double vision;

  
  


• 
  

  ongoing diarrhea or vomiting;

  
  


• 
  

  easy bruising or bleeding, unusual weakness;

  
  


• 
  

  urinating less than usual or not at all;

  
  


• 
  

  feeling short of breath; or

  
  


• 
  

  dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats, seizure).

  
  

Less serious side effects may include:

• 
  

  mild headache, dizziness, drowsiness;

  
  


• 
  

  dry mouth, nose, or throat;

  
  


• 
  

  decreased sense of taste;

  
  


• 
  

  nausea, bloating, constipation;

  
  


• 
  

  blurred vision;

  
  


• 
  

  feeling nervous or restless;

  
  


• 
  

  sleep problems (insomnia); or

  
  


• 
  

  decreased sweating.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine Dosing Information

Usual Adult Dose for Nasal Congestion:

Brompheniramine/chlorpheniramine/methscopolamine/phenylephrine/pseudoephedrine oral kit:
1 AM tablet orally in the morning and 1 PM tablet orally in the evening.

Usual Pediatric Dose for Nasal Congestion:

Brompheniramine/chlorpheniramine/methscopolamine/phenylephrine/pseudoephedrine oral kit:
6 to 11 years: 1 AM tablet orally in the morning and 1/2 PM tablet orally in the evening.
12 years or older: 1 AM tablet orally in the morning and 1 PM tablet orally in the evening.

What other drugs will affect brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine?

Before using this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by chlorpheniramine or methscopolamine.

Tell your doctor about all other medicines you use, especially:

• 
  

  atropine (Atreza, Sal-Tropine);

  
  


• 
  

  benztropine (Cogentin);

  
  


• 
  

  topiramate (Topamax);

  
  


• 
  

  zonisamide (Zonegran);

  
  


• 
  

  anti-nausea medications such as belladonna (Donnatal), dimenhydrinate (Dramamine), droperidol (Inapsine), methscopolamine (Pamine), or scopolamine (Transderm Scop);

  
  


• 
  

  bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), solifenacin (Vesicare), tolterodine (Detrol), or Urogesic Blue;

  
  


• 
  

  bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva);

  
  


• 
  

  irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Hyomax), or propantheline (Pro Banthine); or

  
  


• 
  

  ulcer medicine such as glycopyrrolate (Robinul) or mepenzolate (Cantil).

  
  

This list is not complete and other drugs may interact with brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine resources

• Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine Drug Interactions
• Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine Support Group
• 0 Reviews for Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine - Add your own review/rating

Compare brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine with other medications

• Nasal Congestion

Where can I get more information?

• Your pharmacist can provide more information about brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine.

Flameril

Flameril may be available in the countries listed below.

Ingredient matches for Flameril

Diclofenac

Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Flameril in the following countries:

• Hungary


• Portugal

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Flameril in the following countries:

• New Zealand


• Portugal

International Drug Name Search

Bruzol

Bruzol may be available in the countries listed below.

Ingredient matches for Bruzol

Albendazole

Albendazole is reported as an ingredient of Bruzol in the following countries:

• Mexico

International Drug Name Search

Systen

In the US, Systen is a member of the drug class estrogens and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Breast Cancer - Palliative, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms, Primary Ovarian Failure and Prostate Cancer.

Ingredient matches for Systen

Estradiol

Estradiol is reported as an ingredient of Systen in the following countries:

• Brazil


• France


• Italy


• Luxembourg


• Netherlands


• Poland

Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Systen in the following countries:

• Austria


• Belgium


• Bulgaria


• Czech Republic


• Switzerland

International Drug Name Search

Clonidural

Clonidural may be available in the countries listed below.

Ingredient matches for Clonidural

Clonidine

Clonidine hydrochloride (a derivative of Clonidine) is reported as an ingredient of Clonidural in the following countries:

• Argentina

International Drug Name Search

Limbitrol DS

See also: Generic Limbitrol

Limbitrol DS is a brand name of amitriptyline/chlordiazepoxide, approved by the FDA in the following formulation(s):

LIMBITROL DS (amitriptyline hydrochloride; chlordiazepoxide - tablet; oral)

• 
  Manufacturer: VALEANT PHARM INTL
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): EQ 25MG BASE;10MG ^[RLD][AB]

Has a generic version of Limbitrol DS been approved?

Yes. The following products are equivalent to Limbitrol DS:

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE (amitriptyline hydrochloride; chlordiazepoxide tablet; oral)

• 
  Manufacturer: MYLAN
  
  Approval date: December 10, 1986
  
  Strength(s): EQ 25MG BASE;10MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Limbitrol DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Limbitrol DS.

See also...

• Limbitrol DS Consumer Information (Wolters Kluwer)
• Limbitrol DS Consumer Information (Cerner Multum)
• Limbitrol DS Advanced Consumer Information (Micromedex)
• Amitriptyline/Chlordiazepoxide Consumer Information (Wolters Kluwer)
• Amitriptyline and chlordiazepoxide Consumer Information (Cerner Multum)
• Chlordiazepoxide and amitriptyline Advanced Consumer Information (Micromedex)

P&U Cytarabine

P&U Cytarabine may be available in the countries listed below.

Ingredient matches for P&U Cytarabine

Cytarabine

Cytarabine is reported as an ingredient of P&U Cytarabine in the following countries:

• South Africa

International Drug Name Search

Chloroprocaine

In the US, Chloroprocaine (chloroprocaine systemic) is a member of the drug class local injectable anesthetics and is used to treat Local Anesthesia.

US matches:

• Chloroprocaine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N01BA04

CAS registry number (Chemical Abstracts Service)

0000133-16-4

Chemical Formula

C13-H19-Cl-N2-O2

Molecular Weight

270

Therapeutic Category

Anesthetic, local

Chemical Name

Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester

Foreign Names

• Chloroprocainum (Latin)
• Chloroprocain (German)
• Chloroprocaïne (French)
• Cloroprocaina (Spanish)

Generic Name

• Chloroprocaine Hydrochloride (PH: USP 32)

Brand Names

• Chloroprocaine Hydrochloride
  APP, United States; Bedford, United States; Hospira, United States



• Chloroprocaine
  Abbott, Israel



• Ivracain
  Sintetica, Switzerland



• K.H.3.
  Bamford, New Zealand



• Nesacaine
  APP, United States; AstraZeneca, Canada; AstraZeneca, United States

International Drug Name Search

Glossary

PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Carboplatino Servycal

Carboplatino Servycal may be available in the countries listed below.

Ingredient matches for Carboplatino Servycal

Carboplatin

Carboplatin is reported as an ingredient of Carboplatino Servycal in the following countries:

• Argentina


• Peru

International Drug Name Search

Cephra

Cephra may be available in the countries listed below.

Ingredient matches for Cephra

Cefradine

Cefradine is reported as an ingredient of Cephra in the following countries:

• Bangladesh

International Drug Name Search

Apo-Cetirizine

Apo-Cetirizine may be available in the countries listed below.

Ingredient matches for Apo-Cetirizine

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Apo-Cetirizine in the following countries:

• Canada


• New Zealand

International Drug Name Search

Amoval

Amoval may be available in the countries listed below.

Ingredient matches for Amoval

Amoxicillin

Amoxicillin is reported as an ingredient of Amoval in the following countries:

• Chile


• Peru

International Drug Name Search

Akne BP5

Akne BP5 may be available in the countries listed below.

Ingredient matches for Akne BP5

Benzoyl Peroxide

Benzoyl Peroxide is reported as an ingredient of Akne BP5 in the following countries:

• Bulgaria

International Drug Name Search

Atenolol / Chlortalidone EG

Atenolol / Chlortalidone EG may be available in the countries listed below.

Ingredient matches for Atenolol / Chlortalidone EG

Atenolol

Atenolol is reported as an ingredient of Atenolol / Chlortalidone EG in the following countries:

• Belgium

Chlortalidone

Chlortalidone is reported as an ingredient of Atenolol / Chlortalidone EG in the following countries:

• Belgium

International Drug Name Search

Predsim

Predsim may be available in the countries listed below.

Ingredient matches for Predsim

Prednisolone

Prednisolone 21-(disodium phosphate) (a derivative of Prednisolone) is reported as an ingredient of Predsim in the following countries:

• Brazil

International Drug Name Search

Benzoak

Benzoak may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Benzoak

Benzocaine

Benzocaine is reported as an ingredient of Benzoak in the following countries:

• Norway

International Drug Name Search

Dramin

Dramin may be available in the countries listed below.

Ingredient matches for Dramin

Dimenhydrinate

Dimenhydrinate is reported as an ingredient of Dramin in the following countries:

• Brazil

International Drug Name Search

Ocufen

flurbiprofen sodium

Dosage Form: ophthalmic solution
Ocufen®

(flurbiprofen sodium ophthalmic solution, USP) 0.03%

sterile

DESCRIPTION

Ocufen® (flurbiprofen sodium ophthalmic solution, USP) 0.03% is a sterile topical nonsteroidal anti-inflammatory product for ophthalmic use.

Chemical Name:

Sodium (±)-2-(2-fluoro-4-biphenylyl)-propionate dihydrate.

Structural Formula:

Contains: Active: flurbiprofen sodium 0.03% (0.3 mg/mL). Preservative: thimerosal 0.005%. Inactives: citric acid; edetate disodium; polyvinyl alcohol 1.4%; potassium chloride; purified water; sodium chloride; and sodium citrate. May also contain hydrochloric acid and/or sodium hydroxide to adjust the pH. The pH of Ocufen® ophthalmic solution is 6.0 to 7.0. It has an osmolality of 260 - 330 mOsm/kg.

CLINICAL PHARMACOLOGY

Flurbiprofen sodium is one of a series of phenylalkanoic acids that have shown analgesic, antipyretic, and anti-inflammatory activity in animal inflammatory diseases. Its mechanism of action is believed to be through inhibition of the cyclo-oxygenase enzyme that is essential in the biosynthesis of prostaglandins.

Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed on animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilatation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms. In clinical studies, Ocufen® ophthalmic solution has been shown to inhibit the miosis induced during the course of cataract surgery. Results from clinical studies indicate that flurbiprofen sodium has no significant effect upon intraocular pressure.

INDICATIONS AND USAGE

Ocufen® ophthalmic solution is indicated for the inhibition of intraoperative miosis.

CONTRAINDICATIONS

Ocufen® ophthalmic solution is contraindicated in individuals who are hypersensitive to any components of the medication.

WARNINGS

With nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding due to interference with thrombocyte aggregation. There have been reports that Ocufen® ophthalmic solution may cause increased bleeding of ocular tissues including hyphemas in conjunction with ocular surgery.

There exists the potential for cross-sensitivity to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

PRECAUTIONS

General:

Wound healing may be delayed with the use of Ocufen® (flurbiprofen sodium ophthalmic solution, USP) 0.03%.

It is recommended that Ocufen® ophthalmic solution be used with caution in surgical patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

Drug interactions:

Interaction of Ocufen® ophthalmic solution with other topical ophthalmic medications has not been fully investigated.

Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with Ocufen® ophthalmic solution.

Carcinogenesis, Mutagenesis, Impairment of fertility:

Long-term studies in mice and/or rats have shown no evidence of carcinogenicity with flurbiprofen. Long-term mutagenicity studies in animals have not been performed.

Pregnancy:

Pregnancy category C. Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of 0.4 mg/kg (approximately 300 times the human daily topical dose) and above.

There are no adequate and well-controlled studies in pregnant women. Ocufen® ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from flurbiprofen sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use:

Safety and effectiveness in pediatric patients have not been established.

Geriatric use:

No overall differences in safety or efffectiveness have been observed between elderly and younger patients.

Adverse Reactions

Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of Ocufen® ophthalmic solution. Other adverse reactions reported with the use of Ocufen® ophthalmic solution include: fibrosis, miosis, and mydriasis.

Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported.

OVERDOSAGE

Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.

DOSAGE AND ADMINISTRATION

A total of four (4) drops of Ocufen® ophthalmic solution should be administered by instilling one (1) drop approximately every 1/2 hour beginning 2 hours before surgery.

HOW SUPPLIED

Ocufen® (flurbiprofen sodium ophthalmic solution, USP) is available for topical ophthalmic administration as a 0.03% sterile solution, and is supplied in a white opaque low density polyethylene bottle with a controlled dropper tip and a gray high impact polystyrene cap in the following size:

 

2.5 mL in 5 mL bottle - NDC 11980-801-03.

Note: Store at 15° - 25°C (59°-77°F).

Rx Only

Revised May 2004

© 2004 Allergan, Inc.

Irvine, CA 92612, U.S.A.

® Marks owned by Allergan, Inc.

71587US12P

ALLERGAN

NDC 11980-801-03

Rx Only

Ocufen®

(flurbiprofen

sodium ophthalmic

solution, USP)

0.03%

sterile

2.5 mL

ALLERGAN

NDC 11980-801-03 Rx Only

Ocufen®

(flurbiprofen sodium

ophthalmic solution, USP) 0.03%

2.5 mL sterile

Ocufen  flurbiprofen sodium  solution/ drops

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 11980-801 Route of Administration OPHTHALMIC DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength flurbiprofen sodium (flurbiprofen) flurbiprofen sodium 0.3 mg  in 1 mL

Inactive Ingredients Ingredient Name Strength thimerosal   citric acid monohydrate   edetate disodium   polyvinyl alcohol   potassium chloride   water   sodium chloride   sodium citrate   hydrochloric acid   sodium hydroxide

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 11980-801-03 1 BOTTLE In 1 CARTON contains a BOTTLE, DROPPER 1 2.5 mL In 1 BOTTLE, DROPPER This package is contained within the CARTON (11980-801-03)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019404	01/01/1987

Labeler - Allergan, Inc. (144796497)

Establishment
Name	Address	ID/FEI	Operations
Allergan, Inc.		362898611	MANUFACTURE

Revised: 10/2010Allergan, Inc.

More Ocufen resources

• Ocufen Side Effects (in more detail)
• Ocufen Dosage
• Ocufen Use in Pregnancy & Breastfeeding
• Ocufen Drug Interactions
• Ocufen Support Group
• 0 Reviews for Ocufen - Add your own review/rating

• Ocufen Concise Consumer Information (Cerner Multum)


• Ocufen eent Monograph (AHFS DI)


• Ocufen Drops MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Ocufen with other medications

• Inhibition of Intraoperative Miosis
• Postoperative Ocular Inflammation